| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 14.7MM | +22% |
| Gross Profit | 8.9MM | +12% |
| Cost Of Revenue | 5.7MM | +43% |
| Operating Income | -5.8MM | +25% |
| Operating Expenses | 14.7MM | +17% |
| Net Income | -9.6MM | - |
| R&D | 1.2MM | -2% |
| G&A | 6.7MM | +39% |
| Professional Service | 1.9MM | +2% |
| Interest Expense | 1.1MM | +91% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
CLEARWATER, Fla., April 11, 2024--Apyx® Medical Corporation (NASDAQ:APYX) (the "Apyx Medical"; "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users’ Summit is taking place in Las Vegas from April 12-13, 2024.
One thing we could say about the analysts on Apyx Medical Corporation ( NASDAQ:APYX ) - they aren't optimistic, having...
Shareholders in Apyx Medical Corporation ( NASDAQ:APYX ) had a terrible week, as shares crashed 30% to US$1.25 in the...
Apyx Medical Corporation (NASDAQ:APYX) Q4 2023 Earnings Call Transcript March 21, 2024 Apyx Medical Corporation misses on earnings expectations. Reported EPS is $-0.28 EPS, expectations were $-0.13. APYX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome, ladies […]
As an investor, mistakes are inevitable. But you want to avoid the really big losses like the plague. So spare a...
Q4 2023 Apyx Medical Corp Earnings Call
Apyx (APYX) delivered earnings and revenue surprises of -46.15% and 1.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
CLEARWATER, Fla., March 21, 2024--Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024.
CLEARWATER, Fla., March 04, 2024--Apyx® Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st.
CLEARWATER, Fla., February 21, 2024--Apyx Medical Corporation (Nasdaq: APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that its Renuvion technology will be featured in three educational sessions at the upcoming American Academy of Cosmetic Surgery’s 40th Annual Scientific Meeting, to be held in New Orleans, LA from February 22 – 24.